Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Share:
Related ARIA
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
ARIAD Offers Updated Clinical Data for Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer

Stifel Nicolaus maintained Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and lowered the price target from $27.00 to $26.00.

Stifel Nicolaus noted, "We surveyed 34 hematology/oncology specialists in February. Results continue to suggest best-in-class potential for Iclusig in third-line and later-line therapy but greater uncertainty than before regarding Iclusig's front-line potential on the heels of black box warnings for thrombosis and hepatotoxicity. We decrease our target price to $26 from $27 as we decrease our Iclusig sales and out-year EPS estimates."

Ariad Pharmaceuticals closed at $20.08 on Wednesday.

Latest Ratings for ARIA

DateFirmActionFromTo
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...